Nebenwirkungen · Xigduo
Xigduo 5 mg/850 mg film-coated tablets Xigduo 5 mg/1,000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 13
HOS-128369 · Präparat HOS-096549
Urinary tract infections In the 13-study safety pool, urinary tract infections were more frequently reported for dapagliflozin compared with placebo (4.7% versus 3.5%, respectively; see section 4.4). Most infections were mild to moderate, and subjects responded to an initial course of standard treatment and rarely resulted in discontinuation from dapagliflozin treatment. These infections were more frequent in females, and subjects with a prior history were more likely to have a recurrent infection.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-13T13:14:00Z · SHA-256 5e4e22027f26f36b3af00f1144f882799bae35ea23b1602e05670ab58107afc7 · Passage dffdd974244b8e1f903c83e86b1d774fcc532f7bb2193983c8ced8ad42d4dcef · Zeichen 14315–14818 im Abschnitt